替硝唑(Tinidagole)为60年代后期由国外pfizer公司研制的硝基咪唑类衍生物,是继甲硝唑后投放临床的又一高疗效、短疗程、耐受性好的抗厌氧菌新药。我科根据口腔颌面部感染的细菌学特点,选用替硝唑治疗重症的化脓性冠周炎、蜂窝织炎、颌面开放性创伤,颅颌面/颌颈联合根治手术前后的预防和控制感染,计34例,取得较满意的疗效,现初步总结报道如下。 Tinidagole is a nitroimidazole derivative developed by foreign pfizer in the late 1960s. It is another new anti-anaerobic bacterium with high curative effect, short course of treatment and good tolerance after clinical application of metronidazole. Based on the bacteriological characteristics of oral and maxillofacial infection, we selected tinidazole for the prevention and control of severe suppurative pericoronitis, cellulitis, maxillofacial open trauma, craniomaxillofacial / maxillofacial surgery before and after radical surgery Infection, in 34 cases, to obtain more satisfactory curative effect, are now summarized as follows.